<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p82" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_82{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_82{left:341px;bottom:30px;}
#t3_82{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_82{left:377px;bottom:30px;}
#t5_82{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_82{left:540px;bottom:30px;}
#t7_82{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_82{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_82{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_82{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_82{left:285px;bottom:827px;letter-spacing:-0.37px;word-spacing:0.11px;}
#tc_82{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_82{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_82{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_82{left:1119px;bottom:28px;letter-spacing:0.3px;}
#tg_82{left:36px;bottom:165px;}
#th_82{left:42px;bottom:159px;letter-spacing:0.12px;word-spacing:-0.06px;}
#ti_82{left:317px;bottom:159px;}
#tj_82{left:36px;bottom:148px;}
#tk_82{left:46px;bottom:142px;letter-spacing:0.13px;}
#tl_82{left:261px;bottom:142px;}
#tm_82{left:36px;bottom:131px;}
#tn_82{left:46px;bottom:125px;letter-spacing:0.12px;}
#to_82{left:786px;bottom:125px;letter-spacing:0.19px;}
#tp_82{left:828px;bottom:125px;}
#tq_82{left:836px;bottom:125px;letter-spacing:0.19px;}
#tr_82{left:879px;bottom:125px;}
#ts_82{left:887px;bottom:125px;letter-spacing:0.16px;}
#tt_82{left:941px;bottom:125px;letter-spacing:0.12px;}
#tu_82{left:45px;bottom:108px;letter-spacing:0.12px;}
#tv_82{left:36px;bottom:462px;letter-spacing:-0.1px;}
#tw_82{left:36px;bottom:444px;}
#tx_82{left:42px;bottom:444px;letter-spacing:-0.12px;}
#ty_82{left:103px;bottom:444px;}
#tz_82{left:203px;bottom:778px;letter-spacing:0.44px;}
#t10_82{left:628px;bottom:778px;letter-spacing:0.37px;word-spacing:-0.21px;}
#t11_82{left:614px;bottom:747px;letter-spacing:-0.13px;}
#t12_82{left:636px;bottom:755px;}
#t13_82{left:899px;bottom:756px;letter-spacing:-0.1px;}
#t14_82{left:899px;bottom:738px;letter-spacing:-0.09px;}
#t15_82{left:202px;bottom:677px;letter-spacing:-0.09px;}
#t16_82{left:202px;bottom:659px;letter-spacing:-0.1px;}
#t17_82{left:202px;bottom:640px;letter-spacing:-0.1px;}
#t18_82{left:202px;bottom:622px;letter-spacing:-0.09px;}
#t19_82{left:202px;bottom:482px;letter-spacing:-0.1px;}
#t1a_82{left:202px;bottom:464px;letter-spacing:-0.09px;}
#t1b_82{left:202px;bottom:446px;letter-spacing:-0.1px;}
#t1c_82{left:202px;bottom:427px;letter-spacing:-0.09px;}
#t1d_82{left:202px;bottom:305px;letter-spacing:-0.08px;}
#t1e_82{left:202px;bottom:287px;letter-spacing:-0.11px;}
#t1f_82{left:294px;bottom:295px;}
#t1g_82{left:367px;bottom:724px;letter-spacing:-0.1px;}
#t1h_82{left:493px;bottom:734px;letter-spacing:-0.1px;}
#t1i_82{left:493px;bottom:716px;letter-spacing:-0.1px;}
#t1j_82{left:367px;bottom:565px;letter-spacing:-0.1px;}
#t1k_82{left:367px;bottom:488px;letter-spacing:-0.1px;}
#t1l_82{left:367px;bottom:421px;letter-spacing:-0.1px;}
#t1m_82{left:367px;bottom:330px;letter-spacing:-0.07px;}
#t1n_82{left:367px;bottom:312px;letter-spacing:-0.09px;}
#t1o_82{left:614px;bottom:709px;letter-spacing:-0.1px;}
#t1p_82{left:614px;bottom:690px;letter-spacing:-0.09px;}
#t1q_82{left:614px;bottom:672px;letter-spacing:-0.09px;}
#t1r_82{left:614px;bottom:654px;letter-spacing:-0.09px;}
#t1s_82{left:614px;bottom:635px;letter-spacing:-0.14px;word-spacing:0.03px;}
#t1t_82{left:614px;bottom:617px;letter-spacing:-0.12px;word-spacing:0.02px;}
#t1u_82{left:899px;bottom:690px;letter-spacing:-0.1px;}
#t1v_82{left:998px;bottom:698px;}
#t1w_82{left:899px;bottom:672px;letter-spacing:-0.06px;}
#t1x_82{left:899px;bottom:654px;letter-spacing:-0.1px;}
#t1y_82{left:899px;bottom:635px;letter-spacing:-0.1px;}
#t1z_82{left:367px;bottom:265px;letter-spacing:-0.11px;}
#t20_82{left:546px;bottom:585px;letter-spacing:-0.13px;}
#t21_82{left:569px;bottom:592px;}
#t22_82{left:546px;bottom:567px;letter-spacing:-0.06px;}
#t23_82{left:546px;bottom:548px;letter-spacing:-0.09px;}
#t24_82{left:546px;bottom:508px;letter-spacing:-0.1px;}
#t25_82{left:610px;bottom:515px;}
#t26_82{left:623px;bottom:508px;letter-spacing:-0.09px;}
#t27_82{left:546px;bottom:490px;letter-spacing:-0.06px;}
#t28_82{left:546px;bottom:471px;letter-spacing:-0.11px;word-spacing:0.02px;}
#t29_82{left:546px;bottom:440px;letter-spacing:-0.11px;word-spacing:0.02px;}
#t2a_82{left:546px;bottom:422px;letter-spacing:-0.06px;}
#t2b_82{left:546px;bottom:404px;letter-spacing:-0.1px;}
#t2c_82{left:547px;bottom:320px;letter-spacing:-0.1px;}
#t2d_82{left:696px;bottom:320px;letter-spacing:-0.11px;}
#t2e_82{left:752px;bottom:320px;}
#t2f_82{left:547px;bottom:302px;letter-spacing:-0.1px;}
#t2g_82{left:547px;bottom:284px;letter-spacing:-0.1px;}
#t2h_82{left:547px;bottom:265px;letter-spacing:-0.1px;}
#t2i_82{left:547px;bottom:247px;letter-spacing:-0.1px;}
#t2j_82{left:547px;bottom:229px;letter-spacing:-0.1px;}
#t2k_82{left:547px;bottom:210px;letter-spacing:-0.1px;}
#t2l_82{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_82{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_82{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_82{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_82{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_82{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_82{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_82{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_82{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s8_82{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s9_82{font-size:15px;font-family:Arial-ItalicMT_kb;color:#000;}
.sa_82{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.sb_82{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sc_82{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts82" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg82Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg82" style="-webkit-user-select: none;"><object width="1210" height="935" data="82/82.svg" type="image/svg+xml" id="pdf82" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_82" class="t s0_82">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_82" class="t s1_82">® </span>
<span id="t3_82" class="t s0_82">(NCCN </span>
<span id="t4_82" class="t s1_82">® </span>
<span id="t5_82" class="t s0_82">), All rights reserved. NCCN Guidelines </span>
<span id="t6_82" class="t s1_82">® </span>
<span id="t7_82" class="t s0_82">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_82" class="t s2_82">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_82" class="t s2_82">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_82" class="t s3_82">NCCN Guidelines Version 4.2024 </span>
<span id="tb_82" class="t s3_82">Salivary Gland Tumors </span>
<span id="tc_82" class="t s4_82">NCCN Guidelines Index </span>
<span id="td_82" class="t s4_82">Table of Contents </span>
<span id="te_82" class="t s4_82">Discussion </span>
<span id="tf_82" class="t s5_82">SALI-4 </span>
<span id="tg_82" class="t s6_82">l </span>
<span id="th_82" class="t s7_82">Principles of Radiation Therapy (SALI-A)</span><span id="ti_82" class="t s8_82">. </span>
<span id="tj_82" class="t s6_82">o </span>
<span id="tk_82" class="t s7_82">Principles of Surgery (SURG-A)</span><span id="tl_82" class="t s8_82">. </span>
<span id="tm_82" class="t s6_82">p </span>
<span id="tn_82" class="t s8_82">Use NGS profiling and other appropriate biomarker testing to check status of androgen receptor (AR), HER2, </span><span id="to_82" class="t s9_82">NTRK</span><span id="tp_82" class="t s8_82">, </span><span id="tq_82" class="t s9_82">HRAS</span><span id="tr_82" class="t s8_82">, </span><span id="ts_82" class="t s9_82">PIK3CA</span><span id="tt_82" class="t s8_82">, and tumor mutational burden </span>
<span id="tu_82" class="t s8_82">(TMB) prior to treatment. </span>
<span id="tv_82" class="t s5_82">Follow-up </span>
<span id="tw_82" class="t s5_82">(</span><span id="tx_82" class="t sa_82">FOLL-A</span><span id="ty_82" class="t s5_82">) </span>
<span id="tz_82" class="t s5_82">RECURRENCE </span><span id="t10_82" class="t s5_82">TREATMENT FOR RECURRENCE </span>
<span id="t11_82" class="t s5_82">RT </span>
<span id="t12_82" class="t sb_82">l </span>
<span id="t13_82" class="t s5_82">Follow-up </span>
<span id="t14_82" class="t sa_82">(FOLL-A, 1 of 2) </span>
<span id="t15_82" class="t s5_82">Locoregional </span>
<span id="t16_82" class="t s5_82">recurrence </span>
<span id="t17_82" class="t s5_82">without </span>
<span id="t18_82" class="t s5_82">prior RT </span>
<span id="t19_82" class="t s5_82">Locoregional </span>
<span id="t1a_82" class="t s5_82">recurrence or </span>
<span id="t1b_82" class="t s5_82">second primary </span>
<span id="t1c_82" class="t s5_82">with prior RT </span>
<span id="t1d_82" class="t s5_82">Distant </span>
<span id="t1e_82" class="t s5_82">metastases </span>
<span id="t1f_82" class="t sb_82">p </span>
<span id="t1g_82" class="t s5_82">Resectable </span>
<span id="t1h_82" class="t s5_82">Completely </span>
<span id="t1i_82" class="t s5_82">resected </span>
<span id="t1j_82" class="t s5_82">Unresectable </span>
<span id="t1k_82" class="t s5_82">Resectable </span>
<span id="t1l_82" class="t s5_82">Unresectable </span>
<span id="t1m_82" class="t s5_82">Clinical trial </span>
<span id="t1n_82" class="t s5_82">preferred </span>
<span id="t1o_82" class="t s5_82">Adverse pathologic features: </span>
<span id="t1p_82" class="t s5_82">• Intermediate or high grade </span>
<span id="t1q_82" class="t s5_82">• Close or positive margins </span>
<span id="t1r_82" class="t s5_82">• Neural/perineural invasion </span>
<span id="t1s_82" class="t s5_82">• Lymph node metastases </span>
<span id="t1t_82" class="t s5_82">• Lymphatic/vascular invasion </span>
<span id="t1u_82" class="t s5_82">Adjuvant RT </span>
<span id="t1v_82" class="t sb_82">l </span>
<span id="t1w_82" class="t s5_82">or </span>
<span id="t1x_82" class="t s5_82">Consider systemic </span>
<span id="t1y_82" class="t s5_82">therapy/RT (category 2B) </span>
<span id="t1z_82" class="t s5_82">PS 0–3 </span>
<span id="t20_82" class="t s5_82">RT </span>
<span id="t21_82" class="t sb_82">l </span>
<span id="t22_82" class="t s5_82">or </span>
<span id="t23_82" class="t s5_82">Systemic therapy/RT (category 2B) </span>
<span id="t24_82" class="t s5_82">Surgery </span>
<span id="t25_82" class="t sb_82">o </span>
<span id="t26_82" class="t s5_82">(preferred) </span>
<span id="t27_82" class="t s5_82">or </span>
<span id="t28_82" class="t s5_82">Reirradiation ± systemic therapy, clinical trial preferred </span>
<span id="t29_82" class="t s5_82">Reirradiation ± systemic therapy, clinical trial preferred </span>
<span id="t2a_82" class="t s5_82">or </span>
<span id="t2b_82" class="t s5_82">Systemic therapy (see Distant metastases pathway below) </span>
<span id="t2c_82" class="t s5_82">Systemic therapy (</span><span id="t2d_82" class="t sa_82">SALI-B</span><span id="t2e_82" class="t s5_82">) </span>
<span id="t2f_82" class="t s5_82">or </span>
<span id="t2g_82" class="t s5_82">Expectant management (with slow-growing disease) </span>
<span id="t2h_82" class="t s5_82">or </span>
<span id="t2i_82" class="t s5_82">Selected metastasectomy (category 3) </span>
<span id="t2j_82" class="t s5_82">or </span>
<span id="t2k_82" class="t s5_82">Best supportive care </span>
<span id="t2l_82" class="t sc_82">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
